1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Earnings Recovery For Nichi-Iko Unlikely Before Full Resumption Of Toyama Shipments

Japanese Generics Giant Still Suffering Following The Events Of 2021

 
• By Chloe Kent

Nichi-Iko still has a long road to recovery ahead as it attempts to get its Toyama plant back on its feet.

Recovery Progressive Bar Loading on Computer Laptop Screen At 38%
A long road to recovery awaits Nichi-Iko • Source: Shutterstock

Earnings recovery for Nichi-Iko Pharmaceutical Co., Ltd. appears unlikely until the full resumption of shipments from its Toyama plant. Despite securing a 9.6% year-on-year revenue rise to ¥47bn ($330m) during its financial Q1 ended 30 June 2022 due to increased sales volume, operating losses expanded to ¥6.5bn compared to ¥4.1bn during the prior year.

Nichi-Iko explained that “due to stringent quality checks and other measures, it is talking longer than originally expected to resume full shipments” from its manufacturing facility in the city of Namerikawa, Toyama prefecture

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Anju Ghangurde

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

ANI Raises Generics Guidance As Exclusive Prucalopride Drives Growth

 
• By Dean Rudge

ANI Pharmaceuticals says it has delivered an “exceptionally strong first quarter,” with total sales reaching over $197m, amid plans to kick off a Phase IV clinical trial for Cortrophin Gel for acute gouty arthritis later this year.

Hikma Eyes $5bn Sales Target As It Sets Out Plans To 2030

 
• By Dave Wallace

Unveiling a new name for its generics business, Hikma has at the same time set out medium-term financial goals for its business that include three-year growth objectives for its sales and profits, as well as aiming at a $5bn turnover target by 2030.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

More from Business

J&J Hits Back Over Private-Label Stelara Biosimilar In US

 
• By Dave Wallace

After being refused an injunction as part of ongoing litigation over a private-label ustekinumab biosimilar being marketed in the US by Sandoz and Samsung Bioepis, Stelara originator Johnson & Johnson is continuing to pursue an appeal. However, newly-unsealed court documents suggest the brand company had demonstrated a likelihood of success - and reveal further details about the case, including the identity of the PBM involved and why the injunction request was denied.

Hikma Eyes $5bn Sales Target As It Sets Out Plans To 2030

 
• By Dave Wallace

Unveiling a new name for its generics business, Hikma has at the same time set out medium-term financial goals for its business that include three-year growth objectives for its sales and profits, as well as aiming at a $5bn turnover target by 2030.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.